Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B

BACKGROUND/AIMS: The immune-tolerant (IT) phase of chronic hepatitis B (CHB) patients is not generally indicative of antiviral therapy (AVT). We assessed and compared the risk of hepatocellular carcinoma (HCC) during the IT-phase stringently defined by a low fibrosis-4 (FIB-4) index, compared to tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeon, Mi Young, Kim, Beom Kyung, Lee, Jae Seung, Lee, Hye Won, Park, Jun Yong, Kim, Do Young, Ahn, Sang Hoon, Han, Kwang-Hyub, Kim, Seung Up
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association for the Study of the Liver 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046628/
https://www.ncbi.nlm.nih.gov/pubmed/33317247
http://dx.doi.org/10.3350/cmh.2020.0216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046628/
https://www.ncbi.nlm.nih.gov/pubmed/33317247
http://dx.doi.org/10.3350/cmh.2020.0216

Ejemplares similares